Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Psychogios, L. Palaiodimou, A. Katsanos, G. Magoufis, A. Safouris, O. Kargiotis, S. Spiliopoulos, E. Papageorgiou, Aikaterini Theodorou, K. Voumvourakis, E. Broutzos, E. Stamboulis, G. Tsivgoulis (2021)
Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusionTherapeutic Advances in Neurological Disorders, 14
W. Hacke, G. Albers, Yasir Al-Rawi, J. Bogousslavsky, A. Dávalos, M. Eliasziw, M. Fischer, A. Furlan, M. Kaste, K. Lees, Mariola Soehngen, S. Warach (2005)
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous DesmoteplaseStroke, 36
(2012)
Prevalence of stroke--United States, 2006-2010.MMWR. Morbidity and mortality weekly report, 61 20
A. Burgos, J. Saver (2019)
Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke.Stroke
This RCT demonstrated that TNK is superior to alteplase in achieving recanalization in patients with large vessel occlusions
(•• Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–e418. This study analyzed the pooled data from all the RCTs and concluded that TNK is non-inferior to alteplase with regard to functional outcome, and had a comparable safety profile.)
•• Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–e418. This study analyzed the pooled data from all the RCTs and concluded that TNK is non-inferior to alteplase with regard to functional outcome, and had a comparable safety profile.•• Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–e418. This study analyzed the pooled data from all the RCTs and concluded that TNK is non-inferior to alteplase with regard to functional outcome, and had a comparable safety profile., •• Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–e418. This study analyzed the pooled data from all the RCTs and concluded that TNK is non-inferior to alteplase with regard to functional outcome, and had a comparable safety profile.
Adnan Qureshi, Z. Ali, M. Suri, Stanley Kim, A. Shatla, A. Ringer, Demetrius Lopes, L. Guterman, L. Hopkins (2001)
Intra-arterial Third-generation Recombinant Tissue Plasminogen Activator (Reteplase) for Acute Ischemic StrokeNeurosurgery, 49
N. Modi, N. Fox, F. Clow, P. Tanswell, C. Cannon, F. Werf, E. Braunwald (2000)
Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial InfarctionThe Journal of Clinical Pharmacology, 40
A. Rabinstein (2006)
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous DesmoteplaseYearbook of Neurology and Neurosurgery, 2006
S. Warach, A. Dula, T. Milling (2020)
Tenecteplase Thrombolysis for Acute Ischemic Stroke.Stroke
S. Noble, D. McTavish (2012)
ReteplaseDrugs, 52
S. Coutts, V. Dubuc, J. Mandzia, C. Kenney, A. Demchuk, Eric Smith, S. Subramaniam, M. Goyal, Shivanand Patil, B. Menon, P. Barber, D. Dowlatshahi, Thalia Field, N. Asdaghi, M. Camden, M. Hill (2015)
Tenecteplase–Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke With Proven OcclusionStroke, 46
MW Parsons, F Miteff, GA Bateman, N Spratt, A Loiselle, J Attia (2009)
Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time windowNeurology, 72
K. Mahawish, J. Gommans, T. Kleinig, Bhavesh Lallu, Alicia Tyson, A. Ranta (2021)
Switching to Tenecteplase for Stroke ThrombolysisStroke, 52
M. Etherton, R. Gadhia, L. Schwamm (2020)
Thrombolysis beyond 4.5 h in Acute Ischemic StrokeCurrent Neurology and Neuroscience Reports, 20
K. Jivan, K. Ranchod, G. Modi (2013)
Management of ischaemic stroke in the acute setting: review of the current statusCardiovascular Journal of Africa, 24
Jillian Hall, Jesse Thon, M. Heslin, L. Thau, T. Yeager, Taylor Siegal, N. Vigilante, Scott Kamen, Justin Tiongson, T. Jovin, J. Siegler (2021)
Tenecteplase Improves Door‐to‐Needle Time in Real‐World Acute Stroke TreatmentStroke: Vascular and Interventional Neurology
A. Bivard, Longting Lin, Mark Parsonsb (2013)
Review of Stroke ThrombolyticsJournal of Stroke, 15
C. Bode, M. Ohman, E. Seifried, M. Silver, R. Smalling, M. Verstraete, H. White (1996)
A Review of its Pharmacological Properties and Clinical Efficacy in the Management of Acute Myocardial Infarction
S. Warach, J. Saver (2020)
Stroke Thrombolysis With Tenecteplase to Reduce Emergency Department Spread of Coronavirus Disease 2019 and Shortages of Alteplase.JAMA neurology
Cathy Zhong, James Beharry, Daniel Salazar, K. Smith, S. Withington, B. Campbell, D. Wilson, C. Heron, Deborah Mason, R. Duncan, Jon Reimers, Frances Mein-Smith, William Diprose, P. Barber, A. Ranta, J. Fink, Teddy Wu (2021)
Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic StrokeStroke, 52
N. Logallo, V. Novotny, J. Assmus, C. Kvistad, Lars Alteheld, O. Rønning, B. Thommessen, K. Amthor, H. Ihle-Hansen, M. Kurz, H. Tobro, K. Kaur, M. Stankiewicz, M. Carlsson, Å. Morsund, T. Idicula, A. Aamodt, C. Lund, H. Næss, U. Waje-Andreassen, L. Thomassen (2017)
Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trialThe Lancet Neurology, 16
X Li, L Ling, C Li, Q Ma (2017)
Efficacy and safety of desmoteplase in acute ischemic stroke patients: a systematic review and meta-analysisMedicine (Baltimore), 96
Xuya Huang, B. Cheripelli, S. Lloyd, D. Kalladka, F. Moreton, A. Siddiqui, I. Ford, K. Muir (2015)
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint studyThe Lancet Neurology, 14
This study analyzed the pooled data from all the RCTs and concluded that TNK is non-inferior to alteplase with regard to functional outcome
W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Dávalos, D. Guidetti, V. Larrue, K. Lees, Z. Medeghri, T. Machnig, D. Schneider, R. Kummer, N. Wahlgren, D. Toni (2008)
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.The New England journal of medicine, 359 13
A. Garber, T. Hobbs, S. Rasmussen, Jina Hahn, H. Rodbard (2013)
Reduced Risk of Confirmed Hypoglycemia (Plasma Glucose <2.3 mmol/L) with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes: A Meta-analysis of 5 Randomized TrialsCanadian Journal of Diabetes, 37
E. Haley, J. Thompson, J. Grotta, P. Lyden, T. Hemmen, Devin Brown, C. Fanale, R. Libman, T. Kwiatkowski, R. Llinas, S. Levine, K. Johnston, R. Buchsbaum, Gilberto Levy, B. Levin (2010)
Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical TrialStroke, 41
(2019)
Correction to: Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.Stroke
M. Kate, R. Wannamaker, H. Kamble, Parnian Riaz, L. Gioia, B. Buck, T. Jeerakathil, P. Smyth, A. Shuaib, D. Emery, K. Butcher (2018)
Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom OnsetJournal of Stroke, 20
M. Parsons, N. Spratt, A. Bivard, B. Campbell, K. Chung, F. Miteff, Billy O’Brien, C. Bladin, P. McElduff, C. Allen, G. Bateman, G. Donnan, S. Davis, C. Levi (2012)
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.The New England journal of medicine, 366 12
(Hall J, Thon JM, Heslin M, Thau L, Yeager T, Siegal T, et al. Tenecteplase improves door‐to‐needle time in real‐world acute stroke treatment. Stroke Vasc Interv Neurol. 2021;1(1).)
Hall J, Thon JM, Heslin M, Thau L, Yeager T, Siegal T, et al. Tenecteplase improves door‐to‐needle time in real‐world acute stroke treatment. Stroke Vasc Interv Neurol. 2021;1(1).Hall J, Thon JM, Heslin M, Thau L, Yeager T, Siegal T, et al. Tenecteplase improves door‐to‐needle time in real‐world acute stroke treatment. Stroke Vasc Interv Neurol. 2021;1(1)., Hall J, Thon JM, Heslin M, Thau L, Yeager T, Siegal T, et al. Tenecteplase improves door‐to‐needle time in real‐world acute stroke treatment. Stroke Vasc Interv Neurol. 2021;1(1).
B. Campbell, P. Mitchell, L. Churilov, N. Yassi, T. Kleinig, R. Dowling, B. Yan, Steven Bush, H. Dewey, V. Thijs, R. Scroop, M. Simpson, M. Brooks, H. Asadi, Teddy Wu, D. Shah, T. Wijeratne, T. Ang, F. Miteff, C. Levi, E. Rodrigues, Henry Zhao, P. Salvaris, C. Garcia-Esperon, P. Bailey, H. Rice, L. Villiers, H. Brown, K. Redmond, D. Leggett, J. Fink, W. Collecutt, A. Wong, C. Muller, A. Coulthard, K. Mitchell, J. Clouston, K. Mahady, D. Field, Henry Ma, T. Phan, W. Chong, R. Chandra, L. Slater, M. Krause, T. Harrington, K. Faulder, B. Steinfort, C. Bladin, G. Sharma, Patricia Desmond, M. Parsons, G. Donnan, Stephen Davis (2018)
Tenecteplase versus Alteplase before Thrombectomy for Ischemic StrokeThe New England Journal of Medicine, 378
F. Werf, J. Adgey, D. Ardissino, P. Armstrong, P. Aylward, G. Barbash, A. Betriu, A. Binbrek, R. Califf, R. Diaz, R. Fanebust, K. Fox, C. Granger, J. Heikkilä, S. Husted, P. Janský, A. Langer, E. Lupi, A. Maseri, J. Meyer, J. Mlczoch, D. Mocceti, D. Myburgh, A. Oto, E. Paolasso, K. Pehrsson, R. Seabra‐Gomes, L. Soares-Piegas, D. Sugrue, M. Tendera, E. Topol, P. Toutouzas, A. Vahanian, F. Verheugt, L. Wallentin, H. White (1999)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.Lancet, 354 9180
(2017)
Efficacy and safety of desmoteplase in acute ischemic stroke patients: a systematic review and meta-analysis. Medicine (Baltimore)
Safety and efficacy of tenecteplase in older patients with large vessel occlusion : a pooled analysis of the EXTEND - IA TNK trials
F. Docagne, J. Parcq, R. Lijnen, C. Ali, D. Vivien (2015)
Understanding the Functions of Endogenous and Exogenous Tissue-Type Plasminogen Activator During StrokeStroke, 46
D. Fatovich, S. Macdonald, S. Brown (2012)
Thrombolysis in acute ischaemic strokeThe Lancet, 380
John Warner, Robert Harrington, R. Sacco, Mitchell Elkind (2019)
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke.Stroke
Zhi-jian Lin, Hongyan Qiu, Xiaozhang Tong, Yi Guo, Man-fu Han, Chun-Shui Yang, Kaimin Lin, Jun Wu, Xing Li, Yang Yang (2017)
Evaluation of efficacy and safety of Reteplase and Alteplase in the treatment of hyper-acute cerebral infarctionBioscience Reports, 38
(2005)
Investigators TNKiS. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke
W. Hacke, A. Furlan, Yasir Al-Rawi, A. Dávalos, J. Fiebach, F. Gruber, M. Kaste, L. Lipka, S. Pedraza, P. Ringleb, H. Rowley, D. Schneider, L. Schwamm, Joaquín Leal, M. Söhngen, P. Teal, K. Wilhelm-Ogunbiyi, M. Wintermark, S. Warach (2009)
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled studyThe Lancet Neurology, 8
A. Rabinstein (2009)
Acute ischemic stroke: Imaging-guided tenecteplase treatment in an extended time windowYearbook of Neurology and Neurosurgery, 2009
Purpose of ReviewTo review the current evidence and ongoing clinical trials evaluating the efficacy and safety of tenecteplase (TNK), an alternative tissue plasminogen activator (tPA), in the acute management of arterial ischemic stroke (AIS). To date, alteplase is the only tPA approved by the United States FDA for use in AIS.Recent FindingsThere have been multiple phase two and three trials investigating the safety and efficacy of TNK in AIS. In patients with AIS due to large vessel occlusion, one randomized controlled trial demonstrated superiority of TNK for vessel recanalization rates and long-term functional outcomes when compared to alteplase. A meta-analysis of all phase two and three trials evaluating TNK in AIS concluded that TNK has a comparable safety and efficacy profile to alteplase. The results of these trials prompted new recommendations in the Acute Stroke Guideline published by the AHA suggesting it may be reasonable to use as an alternative to alteplase. Furthermore, recent real-world data has also reported decreased door-to-needle time with TNK utilization.SummaryIn patients with AIS, use of a thrombolytic agent is standard of care and has been shown to reduce neurological disability and improve functional outcome. Randomized controlled trials have demonstrated that TNK is non-inferior to alteplase from a clinical outcome and safety standpoint. The existing data evaluating the efficacy of TNK compared to alteplase in acute AIS within 4.5 h from symptom onset showed no significant difference between these two agents with regard to functional outcome at 90 days but improved median time to treatment and large vessel recanalization in TNK-treated patients. The results from ongoing TNK trials in larger patient cohorts and in wake-up stroke populations will be instrumental to the wide-scale utilization of TNK in acute AIS management.
Current Treatment Options in Cardiovascular Medicine – Springer Journals
Published: Jan 1, 2023
Keywords: Tenecteplase; Ischemic stroke; Thrombolysis
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.